Literature DB >> 11864890

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.

H Funatsu1, H Yamashita, Y Nakanishi, S Hori.   

Abstract

AIMS: To investigate the correlation between the level of angiotensin II and vascular endothelial growth factor (VEGF) in the vitreous fluid and the severity of proliferative diabetic retinopathy (PDR).
METHODS: During vitreoretinal surgery at the Tokyo Women's Medical University, vitreous fluid samples were obtained from 51 eyes of diabetic patients with PDR, six eyes of diabetic patients without retinopathy, and 16 eyes of non-diabetic patients with ocular disease (controls). The VEGF levels in vitreous fluid and plasma were determined by enzyme linked immunosorbent assay, while angiotensin II levels were measured by radioimmunoassay.
RESULTS: The vitreous fluid levels of VEGF and angiotensin II were significantly higher in patients with PDR than in non-diabetic patients or diabetic patients without retinopathy (all p<0.0001). The vitreous fluid level of angiotensin II was significantly correlated with that of VEGF (p<0.0001), and the vitreous concentrations of both VEGF and angiotensin II were significantly higher in patients with active PDR than in those with quiescent PDR (p<0.0001 and p=0.0005, respectively).
CONCLUSION: The authors found that both angiotensin II and VEGF levels were significantly higher in the vitreous fluid of patients with PDR than in that of non-diabetic patients or diabetic patients without retinopathy, and that the levels of both angiotensin II and VEGF were elevated in the active stage of PDR. These findings suggest that angiotensin II contributes to the development and progression of PDR in combination with VEGF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864890      PMCID: PMC1771054          DOI: 10.1136/bjo.86.3.311

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  29 in total

1.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II.

Authors:  M Lonchampt; L Pennel; J Duhault
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

3.  A sensitive radioimmunoassay for the determination of plasma angiotensin II in human subjects.

Authors:  H Kobayashi; K Shimamoto; O Moriguchi; M Miyahara
Journal:  Jpn Circ J       Date:  1979-08

4.  Retinal neovascularization is prevented by blockade of the renin-angiotensin system.

Authors:  C J Moravski; D J Kelly; M E Cooper; R E Gilbert; J F Bertram; S Shahinfar; S L Skinner; J L Wilkinson-Berka
Journal:  Hypertension       Date:  2000-12       Impact factor: 10.190

5.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

6.  Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells.

Authors:  C C Chua; R C Hamdy; B H Chua
Journal:  Biochim Biophys Acta       Date:  1998-02-04

7.  Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells.

Authors:  A Otani; H Takagi; K Suzuma; Y Honda
Journal:  Circ Res       Date:  1998-03-23       Impact factor: 17.367

8.  The 14-year incidence of visual loss in a diabetic population.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

9.  Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders.

Authors:  Y Katsura; T Okano; M Noritake; H Kosano; H Nishigori; S Kado; T Matsuoka
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112

10.  Colorimetry of angiotensin-I converting enzyme activity in serum.

Authors:  Y Kasahara; Y Ashihara
Journal:  Clin Chem       Date:  1981-11       Impact factor: 8.327

View more
  37 in total

Review 1.  Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy.

Authors:  Mohammad Shamsul Ola; Abdullah S Alhomida; Carlos M Ferrario; Sarfaraz Ahmad
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

3.  Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats.

Authors:  Ik Soo Byon; Dong Hyun Lee; Eun Sook Jun; Min Kyu Shin; Sung Who Park; Ji Eun Lee
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

4.  Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial.

Authors:  Farideh Sharifipour; Mohammadreza Razzaghi; Alireza Ramezani; Mohsen Azarmina; Mehdi Yaseri; Roham Soheilian; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2015-08-21       Impact factor: 2.031

5.  Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.

Authors:  H Funatsu; H Yamashita; H Noma; T Mimura; K Sakata; S Hori
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

6.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09

7.  Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy.

Authors:  Kocabora M Selim; Durmaz Sahan; Taskapili Muhittin; Cekic Osman; Ozsutcu Mustafa
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

8.  Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovascular proliferation.

Authors:  Takaki Kobayashi; Shigeki Machida; Takamitsu Fujiwara; Tadashi Ishibe; Daijiro Kurosaka
Journal:  Clin Ophthalmol       Date:  2010-09-20

9.  Human genetics of diabetic retinopathy: current perspectives.

Authors:  Daniel P K Ng
Journal:  J Ophthalmol       Date:  2010-07-13       Impact factor: 1.909

10.  Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy.

Authors:  Shinko Nakamura; Naoko Iwasaki; Hideharu Funatsu; Shigehiko Kitano; Yasuhiko Iwamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.